At the same time, PSMA uptake has been found to be associated with an increasing number of nonprostatic conditions (including infectious/inflammatory processes such as sarcoidosis, benign neoplasms such as meningiomas, and malignancies such as high-grade gliomas), indicating that the marker is not as specific for prostate cancer as once believed [7, 8]. This evidence concerns the gene FOLH1 and glioma.